NRG Oncology

Recent papers from NRG Oncology

1. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast CancerJournal of Clinical Oncology · 2026
2. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialThe Lancet · 2026
3. Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trialNature Medicine · 2026
4. The evolution of RTOG and NRG Oncology CNS tumors clinical trialsJournal of Neuro-Oncology · 2026
5. Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery · 2026
6. Epigenome-wide DNA methylation and genome-wide genotyping in participants entered on NSABP P-1 and P-2 breast cancer prevention trialsBreast Cancer Research · 2026
7. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate CancerJAMA · 2026
8. Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trialAnnals of Oncology · 2026
9. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal CancerJournal of Clinical Oncology · 2026
10. Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR–Positive Early Breast CancerCancer Research Communications · 2026
11. Lumpectomy Margins and Local Recurrence in DCISJAMA Surgery · 2026
12. Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologyJCO Precision Oncology · 2026
13. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell CarcinomaClinical Cancer Research · 2026
14. A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413Cancers · 2026
15. Adjuvant Chemotherapy +/- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848Journal of Clinical Oncology · 2026
16. Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancerAnnals of Oncology · 2026
17. NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.Journal of Clinical Oncology · 2026
18. A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2– breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.Journal of Clinical Oncology · 2026
19. NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.Journal of Clinical Oncology · 2026
20. NRG-HN015: A phase II randomized trial of neoadjuvant chemotherapy or chemo-immunotherapy in patients with recurrent/persistent PD-L1–positive squamous cell carcinoma of the head and neck undergoing salvage surgery.Journal of Clinical Oncology · 2026